Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products

Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products.

Related Keywords

Yangtze River ,China General ,China ,Shanghai ,Hong Kong ,Philadelphia ,Pennsylvania ,United States ,Amoy ,Fujian ,Wuhan ,Hubei ,Hangzhou ,Zhejiang ,Binhui Biopharm ,Lynk Pharma ,Jiangsu Nhwa Pharma ,Ascletis Pharma ,Yangtze River Pharmaceutical Group ,Bloomberg ,Healthcare Fund ,China Securities Index Co ,Korea Samsung Medical Center ,Shanghai Stock Exchange ,Yangtze River Pharmaceutical ,R Bridge Healthcare Fund ,Jiangsu Nhwa ,Quantum Healthcare ,Aimed Bio ,Samsung Medical ,Ligase Dependent Conjugation ,Medicine Index ,China Securities Index ,Juno Therapeutics ,Wuxi Apptec ,Seeking Alpha ,